NCT02564367已完成1 期
Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- number of patients with discontinuation of S-1 due to intolerable adverse reactions
研究概览
简要总结
Multicenter trial in Germany:
Feasibility Study of Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction with the aim to show the feasibility and tolerability of adjuvant S-1 treatment in Caucasian patients and to determine the recommended dose for the treatment regimen.
详细描述
Patients will be enrolled in one cohorts.
Cohort 1 consists of 30 patients who receive S-1 twice daily for 18 cycles (D1-14 q 3 wks).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient signed and dated informed consent before the start of any specific protocol procedures
- •Adult Caucasian patients ≥ 18 years of age
- •Histologically confirmed diagnosis of adenocarcinoma of the stomach and esophagogastric (EG) junction classified as uT2/uT3/uT4, any N category, M0 or any uT, N+, M0 patient (for patients having received neoadjuvant chemotherapy) or pT2/pT3/pT4, any N category, M0 or any pT, N+, M0 (for patients having received primary surgery) according to Union international contre le cancer (UICC) TNM edition
- •R0-resection after neoadjuvant treatment. However, patients can also be included if neoadjuvant treatment could not be performed due to medical indication of primary surgery (perforation, bleeding etc.) or was not performed due to understaging.
- •D2 lymph node dissection performed
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Consent to translational research being performed on tumor tissue of the primary tumor that had been removed during the resection surgery. Translational research will be performed only upon completion of routine histological and pathological evaluations of the tumor
- •Females of childbearing potential (FCBP) must have a negative pregnancy test within 7 days of the first application of study treatment and must agree to use effective contraceptive birth control measures (Pearl Index < 1) during the course of the trial and for at least 6 months after last application of S-
- •Females of childbearing potential (FCBPs) should be included after a confirmed menstrual period (only if applicable, i.e. still having menses) and must have a negative highly sensitive pregnancy test within 7 days prior to the first application of study treatment and must agree to use highly effective contraceptive birth control measures (Pearl Index < 1) during the course of the trial and for at least 6 months after last application of S-
- •Such highly effective birth control methods include:
- •oral, intravaginal, or transdermal combined hormonal contraception associated with inhibition of ovulation
- •oral, injectable, or implantable progesterone-only hormonal contraception associated with inhibition of ovulation
- •intrauterine device
- •intrauterine hormone-releasing system
- •bilateral tubal occlusion
- •commitment to complete abstinence from heterosexual contact
- •A female subject following menarche is considered to be of childbearing potential unless she is naturally amenorrhoeic for ≥ 1 year without an alternative medical reason, or unless she is permanently sterile (permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy).
- •Males must agree not to father a child during the course of the trial and for at least 6 months after last administration of S-1 and must agree to use condoms during the course of the trial and for at least 6 months after last administration of S-1 in case of sexual intercourse with FCBP or pregnant female.
- •Patient must be able to take medication orally within eight weeks after surgery at the start of S-
- •Normal cardiac function demonstrated by Electrocardiogram (ECG) and echocardiogram (LVEF ≥ 55%)
- •Adequate bone marrow, hepatic and renal function defined as
- •Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
- •Haemoglobin ≥ 9 g/dL
- •Platelets ≥ 100 x 10^9/L
- •Albumin ≥ 2.5 g/dL
- •Total bilirubin ≤ 2 mg/dL
- •GOT/AST and GPT/ALT ≤ 3 x Upper normal limit (ULN)
- •Calculated creatinine clearance according to MDRD equation ≥ 50 mL/min
- •Patient's legal capacity to consent to study participation
排除标准
- •Metastatic disease (exclusion of metastatic disease by a postoperative CT or MRI scan of thorax and abdomen within 3 weeks prior to start of adjuvant therapy)
- •Polyneuropathy > grade 1 (NCI CTCAE version 4.0)
- •Evidence of ascites or liver cirrhosis
- •Patient is pregnant or breast-feeding
- •Patient underwent a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment, or there is an anticipated need for major surgical procedure during the course of the study.
- •Heart failure ≥ NYHA functional classification system grade 2
- •Myocardial infarction, unstable angina, cardiac angioplasty or stenting procedure within the last 6 months.
- •Medical history of pulmonary fibrosis or interstitial lung disease (ILD)
- •Active or uncontrolled bacterial, viral, or fungal infection that requires systemic treatment
- •Known HIV-, HBV-, and HCV-infection
- •Concurrent disease or condition that would make the patient inappropriate for study participation or would interfere with the patient's safety.
- •Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
- •Any cancer therapy (chemotherapy, radiation therapy, biologic therapy, immunotherapy, or hormonal therapy) after resection surgery or requirement for concurrent cancer treatment during study treatment with S-
- •Participation in another clinical trial or treatment with an investigational drug after surgery and during study treatment with S-
- •Known immediate or delayed hypersensitivity to any of the active substances of S-1 (tegafur, gimeracil, and oteracil) or to any of the excipients or to drugs chemically related to S-1 (e.g. 5-fluorouracil)
- •History of severe and unexpected reactions to fluoropyrimidine therapy
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •Treatment with DPD inhibitors, including sorivudine or its chemically related analogues such as brivudine within 4 weeks before start of study drug or during study treatment
- •Previous or concurrent malignant tumor disease other than underlying tumor disease with the exception of cervical cancer in situ, adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, superficial bladder tumors (Ta, Tis, and T1) or any curatively treated tumors > 5 years prior to enrolment
- •Known alcohol abuse or drug addiction
研究组 & 干预措施
Treatment
Experimental
First Cohort 1:
(n = 30 patients) 18 cycles S-1
干预措施: S-1 (Drug)
结局指标
主要结局
number of patients with discontinuation of S-1 due to intolerable adverse reactions
时间窗: 12 months
次要结局
- One-year survival rate(1 years)
- Quality of life(12 months)
- One-year relapse-free survival rate(12 months)
- Relapse-free survival(2 years)
- Overall survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal CancerEsophageal CancerNCT02347904Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)40
撤回
3 期
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.Gastric CancerNCT02736552Fudan University
招募中
不适用
Feasibility Study of adjuvant chemotherapy of S-1/Oxaliplatin for patients with Stage III gastric cancer patientsGastric cancerJPRN-UMIN000023261Hamamatsu University School of Medicine25
招募中
2 期
A feasibility study of adjuvant S-1+CDDP for stage III gastric cancerStage III (the 14th edition of staging system of Japanese Classification of Gastric Carcinoma) gastric cancer based on pathological findings after curative resection.JPRN-UMIN000013479Department of Medical Oncology, Toranomon Hospitalnasoi30
Unknown
2 期
A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaResectable Esophageal Squamous Cell CarcinomaNCT04533490The First Affiliated Hospital of Zhengzhou University42